Henry Schein, Inc. HSIC

NASDAQ · Healthcare · Medical - Distribution

$83.52

Close on Fri, 20 Nov 2026 · market value $9.2B

What the price is betting on

Below its record

At $84, the price assumes revenue grows about 2.4% a year for five years, from $13.7B to about $15.2B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes2.4%
Analysts, next two years3.7%
Last 3 years4%

Revenue growth a year. The price figure comes from a reverse DCF at a 8.5% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than HSIC? Check up to 5 of your stocks at once, free, no account.

0$5B$10B$15B$20B$13.7B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$84

Base

$94

Bull

$105

Today $84

  • Bear $84. Cash flow grows 2% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $94. Cash flow grows 4% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $105. Cash flow grows 6% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$13.8B$13.8B, on the path
  3. FY2027$14.1B$14.4B, on the path
  4. FY2028$14.5B$14.9B, on the path
  5. FY2029$14.8B$15.9B, on the path
  6. FY2030$15.2BThe full bet

Each year's revenue at 2.4% growth from $13.7B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Distribution · listed on NASDAQ

Revenue, FY2025
$13.2B
Growth, 3 years a year
4%
Cash margin
4.3%
Net debt
$3.5B
Shares, 3-year change
−14%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.